| LEGEND BIOTECH SP.ADS/2 |
| USA |
| Gesundheit |
| US52490G1022 / A2P5AH |
| 9LB (Frankfurt) / LEGN (NASDAQ) |
| FRA:9LB, ETR:9LB, 9LB:GR, NASDAQ:LEGN |
| - |
| https://www.legendbiotech.. |
|
Legend Biotech Corporation develops, manufactures, and commercializes chimeric antigen receptor T-cell (CAR-T) therapies for oncology and other serious diseases. The company's flagship product is CARVYKTI, a BCMA-targeted CAR-T cell therapy for relap..
>Volltext.. |
| 2958.56 Mio. EUR |
| 2500.48 Mio. EUR |
| 883.53 Mio. EUR |
| -91.37 Mio. EUR |
| -254.84 Mio. EUR |
| -1.38 EUR |
| 354.28 Mio. EUR |
| 772.37 Mio. EUR |
| -165.98 Mio. EUR |
| 1.49 |
| 64.66% |
| -68.01% |
| - |
| - |
| - |
| LEGEND BIOTECH |
| 08.04.26 |
|